# A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

> **NCT05678257** · PHASE2 · TERMINATED · sponsor: **NuCana plc** · enrollment: 180 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Neoplasms
- Colorectal Adenocarcinoma
- Colorectal Cancer Metastatic
- Neoplasm, Colorectal

## Interventions

- **DRUG:** Fosifloxuridine Nafalbenamide
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT05678257
- **Lead sponsor:** NuCana plc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-18
- **Primary completion:** 2024-08-29
- **Final completion:** 2024-08-29
- **Target enrollment:** 180 (ACTUAL)
- **Why stopped:** A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05678257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05678257, "A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05678257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*